Immunotherapy of insulin-dependent diabetes mellitus

Current Opinion in Immunology

Volumn 13, Issue 5, 2001, Pages 601-605

  Bach, J F ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; B LYMPHOCYTE ANTIGEN; BCG VACCINE; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; GLYCOPROTEIN GP 39; HEAT SHOCK PROTEIN; HYBRID PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MONOCLONAL ANTIBODY; Q FEVER VACCINE; RECOMBINANT DNA; T LYMPHOCYTE ANTIBODY; VIRUS DNA;

ANTIGEN SPECIFICITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; PROPHYLAXIS; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 0035479846     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00267-3     Document Type: Review

References (55)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial
3. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion
4. Insulin-dependent diabetes mellitus as an autoimmune disease
5. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
6. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse
7. Peptide therapy for diabetes in NOD mice
8. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
9. Tolerance to islet autoantigens and type I diabetes
10. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
11. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
12. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent
13. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination
14. DNA immunization to prevent autoimmune diabetes
15. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (The IMDIAB VII)
16. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial
17. Induction of autoimmune diabetes by oral administration of autoantigen
18. Potential risk of oral insulin with adjuvant for the prevention of type I diabetes: A protocol effective in NOD mice may exacerbate disease in BB rats
19. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
20. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells
21. + T-cells in beta cell destruction
22. Prevention of diabetes mellitus in the non-obese diabetic mouse strain with monoclonal antibodies against the CD45RB molecule
23. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice
24. Anti-alpha/beta T-cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice
25. Regulatory T-cells: Key controllers of immunologic self-tolerance
26. + immunoregulatory T-cells that control autoimmune diabetes
27. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection
28. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
29. Regulatory T-cells and inflammatory bowel disease
30. CTLA-4 up-regulation plays a role in tolerance mediated by CD45
31. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma
32. Interleukin 12 administration induces T-helper type 1 cells and accelerates autoimmune diabetes in NOD mice
33. Interleukin 4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
34. Immunotherapy of spontaneous type I diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer
35. Biolistic-mediated interleukin-4 gene transfer prevents the onset of type 1 diabetes
36. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity
37. The activity of immunoregulatory T-cells mediating active tolerance is potentiated in non obese diabetic mice mice by an IL4-based retroviral gene therapy
38. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1-lymphocytes - A gene therapy model for autoimmune diabetes
39. T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes
40. Systemic delivery of interleukin-10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice
41. TGF-beta 1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice
42. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice
43. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice
44. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice
45. Pancreas-infiltrating Th1-cells and diabetes develop in IL-12-deficient nonobese diabetic mice
46. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes
47. Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D-3 in combination with a short induction course of cyclosporin A
48. 1α,25-dihydroxy-vitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543)
49. Protective role of infections and vaccinations on autoimmune diseases
50. Complete Freund's adjuvant-induced T-cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice
51. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes
52. Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation
53. Mechanisms of Mycobacterium avium-induced resistance against insulin-dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice: Role of Fas and Th1 cells
54. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: Modulation of spontaneous 60 kDa heat shock protein autoimmunity
55. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study